Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer

Assessing the extent of PI3K pathway activity in cancer is vital to predicting sensitivity to PI3K-targeting drugs, but the best biomarker of PI3K pathway activity in archival tumor specimens is unclear. Here, PI3K pathway activation was assessed, in clinical tissue from 1,021 men with prostate cancers, using multiple pathway nodes that include PTEN, phosphorylated AKT (pAKT), phosphorylated ribosomal protein S6 (pS6), and stathmin. Based on these markers, a 9-point score of PI3K activation was created using the combined intensity of the 4-markers and analyzed its association with proliferation (Ki67), apoptosis (TUNEL), and androgen receptor (AR) status, as well as pathologic features and cancer-specific outcomes. In addition, the PI3K activation score was compared with mRNA expression profiling data for a large subset of men. Interestingly, those tumors with higher PI3K activation scores also had higher Gleason grade (P = 0.006), increased AR (r = 0.37; P < 0.001) and Ki67 (r = 0.24; P < 0.001), and decreased TUNEL (r = −0.12; P = 0.003). Although the PI3K activation score was not associated with an increased risk of lethal outcome, a significant interaction between lethal outcome, Gleason and high PI3K score (P = 0.03) was observed. Finally, enrichment of PI3K-specific pathways was found in the mRNA expression patterns differentiating the low and high PI3K activation scores; thus, the 4-marker IHC score of PI3K pathway activity correlates with features of PI3K activation. Implications: The relationship of this activation score to sensitivity to anti-PI3K agents remains to be tested but may provide more precision guidance when selecting patients for these therapies. Mol Cancer Res; 13(10); 1431–40. ©2015 AACR.

[1]  M. Konopleva,et al.  Integrative Genomic and Proteomic Analysis Of Low-Dose ionizing Irradiation Effects On Bone Marrow Stromal Microenvironment and On Survival Of Pre-Leukemic Cells , 2013 .

[2]  J. Hicks,et al.  An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy , 2012, Cancer.

[3]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[4]  Katja Fall,et al.  Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry , 2012, Journal of Clinical Pathology.

[5]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[7]  R. Smart,et al.  PTEN positively regulates UVB-induced DNA damage repair. , 2011, Cancer research.

[8]  T. Golub,et al.  mRNA expression signature of Gleason grade predicts lethal prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Holzer,et al.  Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks. , 2011, Anticancer research.

[10]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[11]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[12]  J. Lanchbury,et al.  A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[14]  Ruedi Aebersold,et al.  Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[15]  M. Dowsett,et al.  Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer , 2010, Breast Cancer Research.

[16]  Theresa Zhang,et al.  Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors , 2010, Science Translational Medicine.

[17]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[18]  Adrian V. Lee,et al.  Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer , 2010, Breast Cancer Research.

[19]  Paul Ellis,et al.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.

[20]  M. Belvin,et al.  Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models , 2010, Clinical Cancer Research.

[21]  Adam M. Gustafson,et al.  Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development , 2010, Science Translational Medicine.

[22]  C. Le Page,et al.  Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-κB signalling pathway and prognostic significance in prostate cancer , 2010, British Journal of Cancer.

[23]  M. Gerstein,et al.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression , 2010, BMC Medical Genomics.

[24]  M. Loda,et al.  Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis , 2009, Science Signaling.

[25]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[26]  C. Belka,et al.  Analysis of complex protein kinase B signalling pathways in human prostate cancer samples , 2008, BJU international.

[27]  Matthew E Ritchie,et al.  Integrative analysis of RUNX1 downstream pathways and target genes , 2008, BMC Genomics.

[28]  N. Kinukawa,et al.  Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men , 2007, BJU international.

[29]  D. Troyer,et al.  Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation , 2007, Clinical Cancer Research.

[30]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[31]  S. Horvath,et al.  Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer , 2007, Proceedings of the National Academy of Sciences.

[32]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[33]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[34]  Daniel J. Freeman,et al.  PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin* , 2006, Journal of Biological Chemistry.

[35]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[36]  D. Troyer,et al.  Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. , 2005, Endocrine-related cancer.

[37]  T. Pandita,et al.  Lack of PTEN sequesters CHK1 and initiates genetic instability. , 2005, Cancer cell.

[38]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[39]  S. Horvath,et al.  Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer , 2004, Clinical Cancer Research.

[40]  P. Scardino,et al.  High Levels of Phosphorylated Form of Akt-1 in Prostate Cancer and Non-Neoplastic Prostate Tissues Are Strong Predictors of Biochemical Recurrence , 2004, Clinical Cancer Research.

[41]  Thomas Wheeler,et al.  High Level of Androgen Receptor Is Associated With Aggressive Clinicopathologic Features and Decreased Biochemical Recurrence-free Survival in Prostate: Cancer Patients Treated With Radical Prostatectomy , 2004, The American journal of surgical pathology.

[42]  D. Pfaff,et al.  Inhibition of neuronal phenotype by PTEN in PC12 cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[43]  O. Halvorsen,et al.  Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  L. Morel,et al.  Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. , 2002, The Biochemical journal.

[45]  D. Troyer,et al.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  M. Wigler,et al.  Design of a retroviral-mediated ecdysone-inducible system and its application to the expression profiling of the PTEN tumor suppressor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  F. Christians,et al.  PTEN Expression Causes Feedback Upregulation of Insulin Receptor Substrate 2 , 2001, Molecular and Cellular Biology.

[48]  T. Tsunoda,et al.  Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. , 2001, Cancer research.

[49]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. J. Chen,et al.  Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. , 2000, American journal of respiratory cell and molecular biology.

[51]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[52]  E. Rimm,et al.  Prospective study of alcohol consumption and risk of coronary disease in men , 1991, The Lancet.